Bangkok, August 16-18, 2023 - The Asia Health & MEDLAB Asia Pacific exhibition took center stage at the Impact Exhibition Center in Bangkok, Thailand. Renowned as the region's premier event for medical devices and laboratory instruments, MEDLAB Asia drew the attention of over 400 exhibitors from Southeast Asian countries including China, India, Malaysia, Indonesia, Vietnam, and the Philippines. Gathering more than 4,200 professional visitors and over 2,600 experts, scholars, and medical practitioners, the event served as a platform to share the latest research advancements and technological breakthroughs.
Distinguished as a leading provider of medical equipment, Lifotronic’s international marketing team showcased a comprehensive range of innovative in-vitro diagnostic products and versatile solutions at this grand event. Their presence contributed significantly to the advancement of clinical diagnostics and garnered high praise from experts and clients alike.
Distinguished as a leading provider of medical equipment, Lifotronic’s international marketing team showcased a comprehensive range of innovative in-vitro diagnostic products and versatile solutions at this grand event. Their presence contributed significantly to the advancement of clinical diagnostics and garnered high praise from experts and clients alike.
Lifotronic's spotlight was on four major platforms: ECLIA, HPLC (HbA1c), CBC, and POCT. These offerings generated profound interest among professionals.
As a trailblazer in ECLIA technology in China, Lifotronic leveraged years of technical expertise to unveil two flagship products - eCL8000 and eCL9000. eCL8000, renowned for its compact design, rapid 9-minute first result retrieval, and intelligent operating system, proved to be a game-changer for international small and medium-sized laboratories as well as emergency departments. Its accolades included installations in dozens of countries within just two years. The eCL9000, boasting features such as exceptional sensitivity, high-throughput, and connectable, marked a pivotal point for Lifotronic's entry into the global high-end immunoassay market.
Lifotronic's journey in HPLC culminated in the creation of diverse product lines catering to low, mid, and high-end customer segments. The H9/H8/H6 models' soaring export sales solidified the company's position as a leader in China's export market. The recent addition, H100, stands out with rapid, stable performance, and a one-click switch from hemoglobin A1c mode to Thalassemia mode, further cementing Lifotronic's dominance in the high-end market.
Under Lifotronic's subsidiary Wheisman, the AC 310 and AC 610 blood cell analyzers gained immense popularity due to their reliability, aiding clinicians in precise diagnostics. A new addition, the fully automated sample loading blood cell analyzer AC 630, is poised to revolutionize the field by streamlining laboratory operations and enhancing efficiency.
In the realm of POCT, Lifotronic presented a comprehensive solution comprising fluorescent immunoassay chromatography and colloidal gold rapid test. These solutions cater to international small and medium-sized laboratories, covering a wide array of testing domains including infectious diseases, reproductive health, and inflammation.
Distinguished as an exceptional medical equipment supplier, Lifotroninc remains dedicated to its founding principles, consistently striving for innovation. Their commitment ensures the delivery of groundbreaking product solutions that continue to shape the landscape of global clinical diagnostics.
We extend our gratitude for your attention to Lifotronic's highlights and achievements at the MEDLAB Asia exhibition. As we move forward, we pledge to maintain our unwavering dedication and contribute even more profoundly to the advancement of the medical field.